REAL WORLD EVIDENCE: The New Standard of Proof?

REAL WORLD EVIDENCE:
The New Standard of Proof?
29 January 2015: NEW JERSEY
09:30
Delegate arrivals
Welcome introductions
Stuart Cooper
Meeting Chair
CEO Adelphi Group
11:15
12:45
Navigating the choices
A guide to developing effective RWE strategies
that are fit for purpose
Q&A
Neil B. Minkoff, MD
Pathways to value
Framing the role of RWE in the current
healthcare accountability environment
Q&A
Johann Odermann
Chief Medical Officer
EmpiraMed Inc
Managed Markets Consultant
PayerStrat
Coffee
Driving real world decisions:
Ways To Use Real World Data to Optimize
Patient Care
Q&A
Gary K. Rice, RPh, MS, MBA
Towards a common goal
Integrating RWE pre- and post-launch to meet
growing demands of regulators, payers,
physicians and patients
Q&A
Jennifer Cook
Vice President of Clinical Services
Diplomat Specialty Pharmacy
Director Value Insight &
Communications Adelphi Values
* (formerly AstraZeneca)
Lunch
Customer value creation
Data collection systems to create payer,
provider and health system solutions
Q&A
Florian Turk
Panel and Audience Debate
Chaired by Neil B. Minkoff, MD
Shaping up for the challenge
How is our industry evolving to face the new
evidence demands?
Meeting close 15:30
VP Head Global Market Access &
Healthcare Solutions
Glaxo SmithKline
Speaker Bios
Neil B. Minkoff, MD
Chief Medical Officer for EmpiraMed, Inc
Neil B. Minkoff, MD is Chief Medical Officer for EmpiraMed, Inc, working to develop the PRO Portal
for capturing self-reported patient outcomes and clinical information to measure real-world
comparative effectiveness. In 2012 he was appointed as a Commissioner of the Massachusetts
Group Insurance Commission, which provides oversight of health insurance for the Commonwealth
of Massachusetts.
Johann Odermann
Managed Markets Consultant, PayerStrat
As Managed Market Practice Leader, Johann provides payer strategy and marketing consultancy to
pharmaceutical and biotech organizations, drawing on his many years of healthcare industry and
specifically managed market experience.
Jennifer Cook
Director, Value Insight & Communication, Adelphi Values (formerly of AstraZeneca)
Jennifer informs client decisions through the investigation, demonstration and communication of
healthcare value. Immediately prior to joining Adelphi Values she worked as a Global Pricing and
Market Access Director for AstraZeneca, developing payer pricing and market access strategies and
shaping evidence needed for payer value stories, to gain reimbursement deliverables.
Florian Turk
Vice President, Head Global Market Access & Healthcare Solutions, GlaxoSmithKline
Florian is responsible for Global Market Access, Pricing and Healthcare Solutions. His main current
research interest is in behavioral models of patient decision making, health care incentive models,
health system and health care delivery reconfiguration analysis as well as in the development and
implementation of innovative Go-to-Market and commercialization strategies and enabling
organizational designs & principles within the industry.
Gary Rice
Vice President of Clinical Services at Diplomat Specialty Pharmacy:
Gary provides leadership, strategy, and planning for all clinical functions across Diplomat Specialty
Pharmacy. He works closely with Operations, IT, Business Development, Sales and Marketing, and
Managed Markets for tactical positioning and clinical service support from development through
implementation, and over sees clinical initiatives and services.
REAL WORLD EVIDENCE:
The New Standard of Proof?
29 January 2015: NEW JERSEY
The Madison, Morristown, NJ
In this meeting designed for Senior Pharmaceutical Executives across disciplines,
Adelphi invites you to engage in thought-leading debate
“How to demonstrate and communicate the better outcomes that
health systems want and will pay for … are payers and pharma aligned
on the future role of Real World Evidence?”
Why attend?

Hear the views of expert speakers from a payer and pharma perspective

Engage in informed discussion with payers and your peers from leading pharma
companies
Optimize your Real World Evidence strategy
to demonstrate therapeutic value to all stakeholders
Realising value: Meet shifting evidence demands from authorities, budget holders, physicians
and patients to support decisions on your therapies, at launch and beyond
Successful evidence collection: Employ new value models to complement traditional RCT end
points (case study examples of successful US and EU models; how to avoid pitfalls)
Impact on pharma: Debate how major pharma companies are realigning philosophy and
processes to recognize Real World Evidence in product development and commercialization
Effective Communication: Reach your key healthcare audiences with Real World Evidence
that resonates and is relevant to their decision making
Featuring an expert speaker panel